Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
 
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size


 
EDITORIAL
Year : 2007  |  Volume : 2  |  Issue : 2  |  Page : 45-46
Classification of asthma according to revised 2006 GINA: Evolution from severity to control


Allergy and Clinical Immunology, Department of Internal Medicine - Faculty of Medicine - King Abdulaziz University, General Secretary of the Saudi Society of Internal Medicine, Saudi Arabia

Date of Submission20-Feb-2007
Date of Acceptance05-Mar-2007

Correspondence Address:
Emad A Koshak
Allergy and Clinical Immunology, Department of Internal Medicine - Faculty of Medicine - King Abdulaziz University, Secretary General of the Saudi Society of Internal Medicine
Saudi Arabia
Login to access the Email id


DOI: 10.4103/1817-1737.32228

PMID: 19727344

Get Permissions



How to cite this article:
Koshak EA. Classification of asthma according to revised 2006 GINA: Evolution from severity to control. Ann Thorac Med 2007;2:45-6

How to cite this URL:
Koshak EA. Classification of asthma according to revised 2006 GINA: Evolution from severity to control. Ann Thorac Med [serial online] 2007 [cited 2014 Sep 15];2:45-6. Available from: http://www.thoracicmedicine.org/text.asp?2007/2/2/45/32228


Asthma has grown to be one of the leading chronic illnesses throughout the world, affecting more than 300 million people of all ages. When uncontrolled, asthma can place rigorous restrictions on everyday life. On the other hand, there are so many options of therapeutic modalities including both old and more advanced medications for the control of asthma symptoms.

In order to effectively combat any chronic illness, one needs to develop and follow strategic guidelines that optimize its diagnosis, management and control. These guidelines are continuously revised and updazted according to the opinions of experts, knowledge of current scientific research, the appearance of more effective drugs or the inappropriateness in the application of a particular guideline on patients in real life.

In 1993, the Global Initiative for Asthma (GINA) was formed. Its goals and objectives were described in a 1995 NHLBI/WHO Workshop Report, Global Strategy for Asthma Management and Prevention (GSAMP). This report was revised in 2002 and its companion documents have been widely distributed and translated into many languages.

As the GINA committees expanded their work, the report was updated annually. The first update was posted in October 2003, a second in October 2004 and a third in October 2005, each including the impact of publications from January through December of the previous year.

All previous GINA reports recommended the categorization of asthmatics according to their clinical severity into four levels: Intermittent, mild persistent [Table - 1]. Accordingly, this has helped asthma care providers to stratify patients to gain a clear stepwise approach of treatment options.

In January 2004, the GINA executive committee recommended that the report be revised to emphasize asthma management based on clinical control rather than classification of the patient by severity. This important paradigm shift for asthma care reflects the progress that has been made in understanding the impact of the disease and the pharmacologic care of patients.

The entire, newly revised document of November 2006 emphasizes asthma control. There is now good evidence that the clinical manifestations of asthma-symptoms, sleep disturbances, limitations of daily activity, impairment of lung function and use of rescue medications-can be controlled with appropriate treatment.

The document now recommends a classification of asthma by level of control: Controlled, partly controlled or uncontrolled [Table - 2]. This reflects an understanding that asthma severity involves not only the severity of the underlying disease but also its responsiveness to treatment and that severity is not an unvarying feature of an individual patient's asthma but may change over months or years.

Asthma control may be defined in a variety of ways. In general, the term "control" may indicate disease prevention or even cure. However, in asthma, where neither of these are realistic options at present, it refers to control of the manifestations of the disease.

Asthma control means that patients should experience no or minimal symptoms (including at night), have no limitations on their activities (including exercise), have no (or minimal) requirement for rescue medications, have near normal lung function and experience only very infrequent exacerbations [Table - 1],[Table - 2].

Some asthma experts are not yet comfortable with the concept of allowing daytime symptoms twice a week or with the need for reliever rescue treatment twice a week. Additionally, classification of asthma based on severity, according to previous guidelines, is now reserved and recommended only for research purposes.

The role of the healthcare professional is to establish each patient's current level of control and then adjust treatment to gain and maintain control. The new document encourages channeling asthmatics into one of five, rather than four, treatment steps based on the control level, with somewhat extra flexibility and more pharmacological options than before.

This classification based on control level is by far more practical, easier to follow, includes more clinically relevant issues and implies more appropriate decisions on the choice of treatment in a given patient with asthma. In addition, telling the patient that your asthma is controlled or not controlled is more informative than intermittent or persistent asthma, especially when such words are translated into patient's own language.

According to the recent GINA document, many attempts have been made to classify asthma according to etiology, particularly with regard to environmental sensitizing agents (allergic asthma). However, such a classification is limited by the existence of patients in whom no environmental cause can be identified (non allergic asthma). Despite this, an effort to identify allergic asthma should be part of the initial assessment to enable, in some uncontrolled patients, the use of avoidance strategies, allergen-specific immunotherapy and anti-IgE therapy.

In spite of courageous efforts to improve asthma care over the past decade, a preponderance of patients have not benefited from advances in asthma management and many lack even the rudiments of care. A challenge for the next several years is to work with asthma specialists, primary healthcare providers and public health officials in each country to design, implement and evaluate asthma care programs to meet local needs.

Although many doctors dealing with asthma have some skepticism about previous or recent GINA guidelines, nevertheless it is a step forward in winning the fight against asthma.[1]

 
   References Top

1.Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI). Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI): Bethesda (MD); 2006. p. 339. Available from: www.ginasthma.com.  Back to cited text no. 1    



 
 
    Tables

  [Table - 1], [Table - 2]

This article has been cited by
1 The adjuvant effect induced by di-(2-ethylhexyl) phthalate (DEHP) is mediated through oxidative stress in a mouse model of asthma
Huihui You,Shaohui Chen,Lin Mao,Bing Li,Ye Yuan,Rui Li,Xu Yang
Food and Chemical Toxicology. 2014;
[Pubmed]
2 Voriconazole and Posaconazole Improve Asthma Severity in Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitization
Livingstone Chishimba,Robert M Niven,John Cooley,David W Denning
Journal of Asthma. 2012; 49(4): 423
[Pubmed]
3 The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children
Al-Moamary, M.S. and Alhaider, S.A. and Al-Hajjaj, M.S. and Al-Ghobain, M.O. and Idrees, M.M. and Zeitouni, M.O. and Al-Harbi, A.S. and Al Dabbagh, M.M. and Al-Matar, H. and Alorainy, H.S.
Annals of Thoracic Medicine. 2012; 7(4): 175-204
[Pubmed]
4 Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization
Chishimba, L. and Niven, R.M. and Cooley, J. and Denning, D.W.
Journal of Asthma. 2012; 49(4): 423-433
[Pubmed]
5 Utilization and responsiveness of the asthma control test (ACT) at the initiation of therapy for patients with asthma: A randomized controlled trial
Al Moamary, M.S. and Al-Kordi, A.G. and Al Ghobain, M.O. and Tamim, H.M.
BMC Pulmonary Medicine. 2012; 12(14)
[Pubmed]
6 Investigation into the use of complementary and alternative medicine and affecting factors in Turkish asthmatic patients
Tokem, Y. and Aytemur, Z.A. and Yildirim, Y. and Fadiloglu, C.
Journal of Clinical Nursing. 2012; 21(5-6): 698-707
[Pubmed]
7 Analysis of polymorphisms in T H2-associated genes in Russian patients with atopic bronchial asthma
Dmitrieva-Zdorova, E.V. and Voronko, O.E. and Latysheva, E.A. and Storozhakov, G.I. and Archakov, A.I.
Journal of Investigational Allergology and Clinical Immunology. 2012; 22(2): 126-132
[Pubmed]
8 Effect of age on asthma control: results from the National Asthma Survey
Neetu Talreja,Alan P. Baptist
Annals of Allergy, Asthma & Immunology. 2011; 106(1): 24
[Pubmed]
9 CARD15 and TLR4 polymorphisms in atopic bronchial asthma
Voronko, O.E. and Dmitrieva-Zdorova, E.V. and Latysheva, E.A. and Aksenova, M.G. and Storozhakov, G.I. and Bodoev, N.V. and Archakov, A.I.
Molecular Biology. 2011; 45(5): 766-773
[Pubmed]
10 CARD15 and TLR4 polymorphisms in atopic bronchial asthma
O. E. Voronko, E. V. Dmitrieva-Zdorova, E. A. Latysheva, M. G. Aksenova, G. I. Storozhakov, N. V. Bodoev, A. I. Archakov
Molecular Biology. 2011; 45(5): 766
[VIEW]
11 Investigation into the use of complementary and alternative medicine and affecting factors in Turkish asthmatic patients : Use of CAM in Turkish asthma patients
Yasemin Tokem, Zeynep Ayfer Aytemur, Yasemin Yildirim, Cicek Fadiloglu
Journal of Clinical Nursing. 2011; : no
[VIEW]
12 Asthma Education for Older Adults: Results from the National Asthma Survey
Alan P. Baptist, Neetu Talreja, Noreen M. Clark
Journal of Asthma. 2011; 48(2): 133
[VIEW]
13 Effect of age on asthma control: Results from the National Asthma Survey
Talreja, N., Baptist, A.P.
Annals of Allergy, Asthma and Immunology. 2011; 106(1): 24-29
[Pubmed]
14 Asthme et tuberculose : association bénéfique ou maléfique ?
L. Fekih,L. Boussoffara,M. Jemaa,S. Fenniche,H. Hassene,D. Belhabib,M.L. Megdiche
Revue des Maladies Respiratoires. 2010; 27(7): 679
[Pubmed]
15 Tuberculosis in patients with asthma | [Asthme et tuberculose: Association bénéfique ou maléfique?]
Fekih, L., Boussoffara, L., Jemaa, M., Fenniche, S., Hassene, H., Belhabib, D., Megdiche, M.L.
Revue des Maladies Respiratoires. 2010; 27(7): 679-684
[Pubmed]
16 Tuberculosis in patients with asthma [Asthme et tuberculose: Association bénéfique ou maléfique?]
Fekih, L. and Boussoffara, L. and Jemaa, M. and Fenniche, S. and Hassene, H. and Belhabib, D. and Megdiche, M.L.
Revue des Maladies Respiratoires. 2010; 27(7): 679-684
[Pubmed]
17 New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist
Koshak, E.A.
Annals of Thoracic Medicine. 2010; 5(2): 65-66
[Pubmed]
18 Association of interleukin-13 gene polymorphisms with atopic bronchial asthma
E. V. Dmitrieva-Zdorova, O. E. Voronko, M. G. Aksenova, N. V. Bodoev
Russian Journal of Genetics. 2010; 46(1): 99-104
[Pubmed]
19 New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist
Koshak, E.A.
Annals of Thoracic Medicine. 2010; 5(2): 65-66
[Pubmed]
20 The Saudi initiative for asthma
Al-Moamary, M., Al-Hajjaj, M., Idrees, M., Zeitouni, M., Alanezi, M., Al-Jahdal, H., Al Dabbagh, M.
Annals of Thoracic Medicine. 2009; 4(4): 216-233
[Pubmed]
21 C-reactive protein monitoring in children with acute asthma | [Praćenje koncentracije C-reaktivnog proteina u djece s astmom]
Raos, M., Dodig, S.
Paediatria Croatica. 2007; 51(3): 105-109
[Pubmed]



 

Top
Print this article  Email this article
 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (94 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Tables

 Article Access Statistics
    Viewed21231    
    Printed364    
    Emailed8    
    PDF Downloaded1426    
    Comments [Add]    
    Cited by others 21    

Recommend this journal